Demetrios Braddock
About Demetrios Braddock
Demetrios Braddock serves as the Scientific Founder at Inozyme Pharma and is an Associate Professor at Yale University, focusing on rare diseases affecting children. His research emphasizes elucidating disease pathogenesis and developing novel biologics to address rare metabolic diseases.
Work at Inozyme
Demetrios Braddock has served as the Scientific Founder at Inozyme Pharma since 2017. In this role, he has been instrumental in advancing the company's mission to develop innovative therapies for rare diseases. His work focuses on elucidating disease mechanisms and identifying therapeutic targets, particularly in conditions that affect children. The company is based in Cambridge, MA, where Braddock has contributed to the design and engineering of novel biologics aimed at improving disease outcomes.
Education and Expertise
Demetrios Braddock holds an MD/PhD from The University of Chicago Pritzker School of Medicine, where he studied Biochemistry and Medicine from 1988 to 1996. He also earned a Bachelor of Arts in Chemistry from the University of Chicago from 1984 to 1988. His academic background provides a strong foundation for his research interests, particularly in rare metabolic diseases and their associated vascular calcification. He practices hematopathology and has extensive training in pathology and chemical physics.
Background
Braddock has a diverse professional background, including significant roles at prestigious institutions. He worked as a Senior Regulatory Research Supervisor at the FDA for 10 months in 2002-2003. Prior to that, he was a Research Associate at the National Institutes of Health from 2000 to 2002 and a Clinical Fellow at the National Cancer Institute from 1996 to 2000. His experience in these roles has contributed to his expertise in disease pathogenesis and biophysical chemistry.
Achievements
As an Associate Professor at Yale University since 2004, Demetrios Braddock has made significant contributions to the understanding of histopathology related to disorders of aberrant calcification. He leads a laboratory focused on investigating disease pathogenesis, particularly in rare diseases affecting children. His research aims to unveil therapeutic targets and has implications for the development of novel treatment strategies in the field of rare metabolic diseases.